
Neuromodulation Publishes 36-Month CORE-VNS Results Showing Sustained Benefits of LivaNova’s VNS Therapy for Drug-Resistant Epilepsy
LivaNova Reports 36-Month CORE-VNS Study Results Showing Sustained Seizure Reduction and Improved Quality of Life in Drug-Resistant Epilepsy LivaNova PLC, a medical technology company specializing in therapies for neurological and…














